Company Monitoring Page for Novartis

latest headlines for company on cafepharma

3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Tags:
Global Blood Therapeutics, sickle cell disease, Oxbryta, Novartis, SCD, Adakveo, Alnylam, Givlaari, acute hepatic porphyria, FDA
Top Biopharma M&As in 2019
BioSpace
Fri, 01/3/20 - 10:06 am
Tags:
M&A, Bristol-Myers Squibb, Celgene, AbbVie, Allergan, Roche, Spark Therapeutics, Novartis, The Medicines Company, Alkermes, Rodin Therapeutics, Sumitomo Dainippon, Roivant
Four Major Biopharma Scandals in 2019
BioSpace
Thu, 01/2/20 - 10:44 am
Tags:
scandal, Novartis, Zolgensma, data manipulation, China, CRISPR, IP theft, Purdue Pharma, Sackler family, oxycontin
Is there a future for pharma in neuro?
Fierce Biotech
Sun, 12/22/19 - 12:25 am
Tags:
Neuroscience, R&D, Eli Lilly, Amgen, GSK, Novartis
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveaway
Fierce Pharma
Thu, 12/19/19 - 12:57 pm
Tags:
Novartis, Zolgensma, SMA, gene therapy, drug pricing, patients
Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis
Endpoints
Thu, 12/19/19 - 12:51 pm
Tags:
Novartis, Akcea, Ionis, AKCEA-APO(a)-L, ACEKA-APOCIII-L
Aduro stung as Novartis drops work on STING drug
Fierce Biotech
Wed, 12/18/19 - 10:34 am
Tags:
Aduro BioTech, Novartis, SEC, ADU-S100
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Tue, 12/17/19 - 10:34 am
Tags:
Novartis, Europe, GSK, Sanofi, AstraZeneca, Roche
How Novartis' cancer drug Tasigna restores critical dopamine that's lost to Parkinson's disease
Fierce Biotech
Tue, 12/17/19 - 10:26 am
Tags:
Tasigna, Novartis, Parkinson's Disease
Novartis axes asthma drug fevipiprant after more trial woes
Pharmaforum
Mon, 12/16/19 - 10:56 am
Tags:
Novartis, asthma, fevipiprant, clinical trials
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Biopharma Dive
Wed, 12/11/19 - 09:59 pm
Tags:
ASH2019, Novartis, FDA, CAR-T, drug manufacturing, Kymriah
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Tue, 12/10/19 - 10:06 am
Tags:
Novartis, Kymriah, CAR-T, DLBCL, ALL
Drug Launch of the Year: Zolgensma
Biopharma Dive
Mon, 12/9/19 - 09:50 am
Tags:
drug launches, Novartis, Zolgensma, SMA
With EMA review in progress, Novartis unveils more positive data on asthma therapy
Endpoints
Fri, 12/6/19 - 10:27 am
Tags:
Novartis, EMA, asthma, QMF149, clinical trials
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Fri, 12/6/19 - 09:54 am
Tags:
Novartis, FDA, Gilenya, MS, multiple sclerosis, Mylan, Dr Reddy's, Torrent Pharmaceuticals, Aurobindo, generics
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Pharmaforum
Fri, 12/6/19 - 09:51 am
Tags:
Novartis, Roche, SMA, risdiplam, branaplam
Novartis says mid-stage pipeline is setting up strong growth spurt
Pharmaforum
Thu, 12/5/19 - 10:26 am
Tags:
Novartis, Pharma CEOs, Vas Narasimhan, R&D, clinical trials
Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain
Pharmaforum
Thu, 12/5/19 - 10:04 am
Tags:
Novartis, Amazon, drug manufacturing, distribution
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
Wed, 12/4/19 - 10:02 am
Tags:
gene therapy, Astellas, Audentes Therapeutics, M&A, Novartis, Medicines Company
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Mon, 12/2/19 - 11:59 pm
Tags:
Novartis, Medicines Company, M&A, inclisiran

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.